medigraphic.com

2011, Número 2

<< Anterior Siguiente >>

Cir Cir 2011; 79 (2)


Relación triglicéridos/colesterol-HDL elevada y resistencia a la insulina

González-Chávez A, Simental-Mendía LE, Elizondo-Argueta S

Idioma: Español
Referencias bibliográficas: 38
Paginas: 126-131
Archivo PDF: 328.10 Kb.


RESUMEN

Introducción: La enfermedad cardiovascular es la principal causa de muerte en el mundo y la resistencia a la insulina desempeña un papel fundamental para su desarrollo. Además, la resistencia a la insulina se ha asociado con hipertensión arterial sistémica y síndrome metabólico, al igual que la relación triglicéridos/colesterol-HDL (TGL/HDL). Objetivo: determinar si la relación TGL/HDL está asociada con resistencia a la insulina en una población aparentemente sana.
Material y métodos: Estudio transversal comparativo en el que se incluyeron individuos aparentemente sanos, hombres y mujeres no embarazadas mayores de 18 años. Los sujetos fueron asignados dentro de los grupos con y sin resistencia a la insulina, pareados por edad, sexo, índice de masa corporal y circunferencia de cintura. La presencia de enfermedades crónicas, como enfermedad renal, hepática, neoplasias o diabetes fueron criterios de exclusión.
Resultados: Se trató de 177 sujetos incluidos, 117 fueron mujeres (66.1%) y 60 hombres (33.9%); de éstos, 145 sujetos (93 mujeres y 52 hombres) con resistencia a la insulina fueron comparados contra 32 (24 mujeres y 8 hombres) sin resistencia. La relación TGL/HDL elevada fue detectada en 89 (61.4%) y 12 (38.6%) sujetos con y sin resistencia a la insulina, respectivamente. La relación TGL/HDL elevada se asoció significativamente con resistencia a la insulina (OR = 2.64, IC 95% = 1.12-6.29).
Conclusiones: La relación TGL/HDL elevada estuvo asociada significativamente con la resistencia a la insulina en sujetos aparentemente sanos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, et al. American Heart Association, Heart disease and stroke statistics 2008 update. Circulation 2008;117:25-46.

  2. Katsanos CS, Aarsland A, Cree MG, Wolfe R. Muscle protein synthesis and balance responsiveness to essential ingestion in the presence of elevated plasma free fatty acid concentration. J Clin Endocrinol Metab 2009;94:2984-2990.

  3. Goff DC, Bertoni AG. Dyslipidemia prevalence, treatment and control in the multi-ethnic study of atherosclerosis (MESNA). Circulation 2006;113:647–656.

  4. González CA, Amancio ChO, Islas AS, Revilla MC, Hernández QM, Lara EA, et al. Factores de riesgo cardiovascular asociados a obesidad abdominal en adultos aparentemente sanos. Rev Med Inst Mex Seguro Soc 2008;46:273-279.

  5. Vasudevan RA, Ballantyne C. Cardiometabolic risk assessment: an approach to the prevention of cardiovascular disease and diabetes mellitus. Clin Cornerstone 2005;7:7-16.

  6. Grundy MS, Pasternak R, Greenland P, Smith S, Fuster V. Assessment of cardiovascular risk by use of multiple risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999;100:1481-1492.

  7. Cordero A, Laclaustra M, León M, Casasnovas J, Grima A, Luengo E, et al. Comparison of serum lipid values in subjects with and without the metabolic syndrome. Am J Cardiol 2008;102:424-428.

  8. Cordero A, Laclaustra M, Leon M, Grima A, Casasnovas J, Luengo E, et al. Prehypertension is associated with insulin resistance state and not with an initial renal function impairment. A Metabolic Syndrome in Active Subjects in Spain (MESYAS). Am J Hypertens 2006;19:189–196.

  9. Hsueh W, Lyon C, Quiñones M. Insulin resistance and the endothelium. Am J Med 2004;117:235-241.

  10. González MA, Selwyn AP. Endothelial function, inflammation, and prognosis in cardiovascular disease. Am J Med, 2003; 115: 99-106.

  11. González CHA, Malanco HL, Sánchez ZM, Elizondo AS, Navarro SJE, Rosillo RS. Inflamación y resistencia a la insulina: mecanismos para el desarrollo de la disfunción endotelial y ateroesclerosis. Am J Med 2003;115:99-106.

  12. Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2006;47:1093-1100.

  13. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and Bcell function from fasting plasma glucose and insulin concentrations in man. Diabetología 1985;28:412-419.

  14. Boizel R, Benhamou PY, Lardy B, Laporte F, Foulon T, Halimi S. Ratio of triglycerides to HDL cholesterol is an indicator of LDL particle size in patients with type 2 diabetes and normal HDL cholesterol levels. Diabetes Care 2000;23:1679–1685.

  15. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1999;22(suppl 1):S5-S19.

  16. National Heart Lung and Blood Institute. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-1252.

  17. Warnick GR, Albers JJ. Heparin-Mn2+ quantitation of high density lipoprotein cholesterol: an ultrafiltration procedure for lipemic samples. J Clin Chem Biochem 1978;24:900-904.

  18. Friedewald WT, Kevy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use the preparative ultracentrifuge. J Clin Chem Biochem 1972;18:499-502.

  19. Arslanian SA, Saad R, Lewy V, Danadian K, Janosky J. Hyperinsulinemia in African. American children: decreased insulin clearance and increased insulin secretion and its relationship to sensitivity. Diabetes 2002;51:3014-3019.

  20. Rader DJ. Effect of insulin resistance, dyslipidemia and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. Am J Med 2007;120(suppl 1):S12-S18.

  21. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006;444:881-887.

  22. De Fronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:214-223.

  23. Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord 2008;6:299-304.

  24. Chan DC, Watts GF, Barrett PH, Mamo JCL, Redgrave TG. Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity. Clin Chem 2002;48:278–283.

  25. Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol 1999;84:1513–1517.

  26. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999;107:450–455.

  27. Ryysy L, Hakkinen AM, Goto T, Vehkavaara S, Westerbacka J, Halavaara J, et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000;49:749–758.

  28. Phillips DI, Caddy S, Ilic V, Fielding BA, Frayn KN, Borthwick AC, et al. Intramuscular triglyceride and muscle insulin sensitivity: evidence for a relationship in nondiabetic subjects. Metabolism 1996;45:947–950.

  29. Goodpaster BH, Thaete FL, Simoneau JA, Kelley DE. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 1997;46:1579–1585.

  30. Pan DA, Lillioja S, Kriketos AD, Milner MR, Baur LA, Bogardus C, et al. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes 1997;46:983–988.

  31. Krssak M, Petersen KF, Bergeron R, Price T, Laurent D, Rothman DL, et al. Intramuscular glycogen and intramyocellular lipid utilization during prolonged exercise and recovery in man: a 13C and 1H nuclear magnetic resonance spectroscopy study. J Clin Endocrinol Metab 2000;85:748–754.

  32. Sumner AE, Finley KB, Genovese DJ, Criqui HM, Boston CR. Fasting triglyceride and the triglyceride-HDL cholesterol ratio are not markers of insulin resistance in African Americans. Arch Intern Med 2005;165:1395-1400.

  33. Bittner V, Johnson D, Zineh I, Rogers WJ, Vido D, Marroquin OC. et al. The triglyceride/high-density lipoprotein cholesterol ratio predicts all cause-mortality in women with suspected myocardial ischemia: a report from the Women’s Ischemia Syndrome Evaluation (WISE). Am Heart J 2009;157:548-555.

  34. Kannel WB, Vasan RS, Keyes MJ. Usefulness of the triglyceride-highdensity lipoprotein versus the cholesterol-high-density lipoprotein ratio for predicting insulin resistance and cardiometabolic risk (from the Framingham offspring cohort). Am J Cardiol 2008;101:497–501.

  35. National Cholesterol Education Program. Detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation 2002;106:3143-3421.

  36. Grundy SM, Brewer HB, Cleeman JI, Smith S, Lenfant C. Definition of metabolic syndrome report of the National Heart, Lung and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004;109:433-438.

  37. Natarajan P, Ray K, Cannon Ch. High-density lipoprotein and coronary heart disease. State of the art. J Am Coll Cardiol 2010;55:1283-1299.




2020     |     www.medigraphic.com